Double role of Fas ligand in the apoptosis of intervertebral disc cells in vitro

Acta Biochimica et Biophysica Sinica

Volumn 41, Issue 11, 2009, Pages 938-947

  Han, Dunfu ^a   Ding, Yue ^a   Liu, Shang Li ^a   Wang, Gang ^a   Si, In Cheong ^a   Wang, Xinguang ^a   Cui, Liyang ^a,b   Huang, Dongshang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Apoptosis; Fas; Fas ligand; Intervertebral disc; RNA interference

Indexed keywords

FAS ANTIGEN; FAS LIGAND; TNFRSF6 PROTEIN, RAT;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; IN VITRO STUDY; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK HERNIA; MALE; METABOLISM; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELLS, CULTURED; FAS LIGAND PROTEIN; INTERVERTEBRAL DISK; INTERVERTEBRAL DISK DISPLACEMENT; MALE; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 70449642859     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmp087     Document Type: Article

References (34)

1. Adams MA and Roughley PJ. What is intervertebral disc degeneration, and what causes it? Spine 2006, 18: 2151-2161.
2. Zhao CQ, Jiang LS and Dai LY. Programmed cell death in intervertebral disc degeneration. Apoptosis 2006, 11: 2079-2088.
3. Gruber HE and Hanley EN, Jr. Analysis of aging and degeneration of the human intervertebral disc: comparison of surgical specimens with normal controls. Spine 1998, 23: 751-757.
4. Park JB, Kim KW, Han CW and Chang H. Expression of Fas receptor on disc cells in herniated lumbar disc tissue. Spine 2001, 26: 142-146. (Pubitemid 32115603)
5. Park JB, Chang H and Kim KW. Expression of Fas ligand and apoptosis of disc cells in herniated lumbar disc tissue. Spine 2001, 26: 618-621. (Pubitemid 32231549)
6. Park JB, Park IC, Park SJ, Jin HO, Lee JK and Riew KD. Anti-apoptotic effects of caspase inhibitors on rat intervertebral disc cells. J Bone Joint Surg Am 2006, 88: 771-779.
7. Chowdhury I, Tharakan B and Bhat GK. Current concepts in apoptosis: the physiological suicide program revisited. Cell Mol Biol Lett 2006, 11: 506-525.
8. Suda T, Takahashi T, Golstein P and Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75: 1169-1178.
9. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A and Duke RC. A role for CD95 ligand in preventing graft rejection. Nature 1995, 377: 630-632.
10. Griffith TS, Brunner T, Fletcher SM, Green DR and Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995, 270: 1189-1192.
11. Bechmann I, Mor G, Nilsen J, Eliza M, Nitsch R and Naftolin F. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: evidence for the existence of an immunological brain barrier. GLIA 1999, 27: 62-74.
12. O'Connell J, Houston A, Bennett MW, O'Sullivan GC and Shanahan F. Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat Med 2001, 7: 271-274.
13. Park H, Jung YK, Park OJ, Lee YJ, Choi JY and Choi Y. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 2005, 175: 7193-7201.
14. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S and Suda T. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nat Med 1998, 4: 1287-1292.
15. Tanaka M, Suda T, Takahashi T and Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J 1995, 14: 1129-1135.
16. Takada T, Nishida K, Doita M and Kurosaka M. Fas ligand exists on intervertebral disc cells: a potential molecular mechanism for immune privilege of the disc. Spine 2002, 27: 1526-1530.
17. Wang J, Tang T, Yang H, Yao X, Chen L, Liu W and Li T. The expression of Fas ligand on normal and stabbed-disc cells in a rabbit model of intervertebral disc degeneration: a possible pathogenesis. J Neurosurg Spine 2007, 6: 425-430.
18. Inui Y, Nishida K, Doita M, Takada T, Miyamoto H, Yoshiya S and Kurosaka M. Fas-ligand expression on nucleus pulposus begins in developing embryo. Spine 2004, 29: 2365-2369.
19. Kaneyama S, Nishida K, Takada T, Suzuki T, Shimomura T, Maeno K and Kurosaka M, et al. Fas ligand expression on human nucleus pulposus cells decreases with disc degeneration processes. J Orthop Sci 2008, 13: 130-135.
20. Cui LY, Liu SL, Ding Y, Huang DS, Ma RF, Huang WG and Hu BS, et al. IL-1β sensitizes rat intervertebral disc cells to Fas ligand mediated apoptosis in vitro. Acta Pharmacol Sin 2007, 28: 1671-1676.
21. Ozeki N, Mogi M, Nakamura H and Togari A. Differential expression of the Fas-Fas ligand system on cytokine-induced apoptotic cell death in mouse osteoblastic cells. Arch Oral Biol 2002, 47: 511-517.
22. Shen J, Liu J, Long Y, Miao Y, Su M, Zhang Q and Han H, et al. Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim Biophys Sin 2009, 41: 223-230.
23. Huang F, Tong X, Fu L and Zhang R. Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivo. Acta Biochim Biophys Sin 2008, 40: 519-525.
24. Huber LC, Distler O, Gay RE and Gay S. Antisense strategies in degenerative joint diseases: sense or nonsense? Adv Drug Deliv Rev 2006, 58: 285-299.
25. Kim DH and Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8: 173-184.
26. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J and Chen J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003, 9: 347-351.
27. Kakutani K, Nishida K, Uno K, Takada T, Shimomura T, Maeno K and Kurosaka M, et al. Prolonged down regulation of specific gene expression in nucleus pulposus cell mediated by RNA interference in vitro. J Orthop Res 2006, 24: 1271-1278.
28. Tsai TT, Danielson KG, Guttapalli A, Oguz E, Albert TJ, Shapiro IM and Risbud MV. TonEBP/OREBP is a regulator of nucleus pulposus cell function and survival in the intervertebral disc. J Biol Chem 2006, 281: 25416-25424.
29. Tsai TT, Guttapalli A, Agrawal A, Albert TJ, Shapiro IM and Risbud MV. MEK/ERK signaling controls osmoregulation of nucleus pulposus cells of the intervertebral disc by transactivation of TonEBP/OREBP. J Bone Miner Res 2007, 22: 965-974.
30. Zeng Y, Danielson KG, Albert TJ, Shapiro IM and Risbud MV. HIF-1 alpha is a regulator of galectin-3 expression in the intervertebral disc. J Bone Miner Res 2007, 22: 1851-1861.
31. Suzuki T, Nishida K, Kakutani K, Maeno K, Yurube T, Takada T and Kurosaka M, et al. Sustained long-term RNA interference in nucleus pulposus cells in vivo mediated by unmodified small interfering RNA. Eur Spine J 2009, 18: 263-270.
32. Nishida K, Suzuki T, Kakutani K, Yurube T, Maeno K, Kurosaka M and Doita M. Gene therapy approach for disc degeneration and associated spinal disorders. Eur Spine J 2008, 17: S459-S466.
33. Klatt AR, Klinger G, Zech D, Paul-Klausch B, Renno JH, Schmidt J and Malchau G, et al. RNAi in primary human chondrocytes: efficiencies, kinetics, and non-specific effects of siRNA-mediated gene suppression. Biologicals 2007, 35: 321-328.
34. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC and Shi Y. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002, 99: 5515-5520.